Advances in Treatment of Progressive Multifocal Leukoencephalopathy.

Fiche du document

Auteurs
Types de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1002/ana.26198

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34405435

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1531-8249

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_5997F734CF2C8

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/

Mots-clés 0

Adoptive Transfer/methods; Humans; Immune Checkpoint Inhibitors/therapeutic use; Leukoencephalopathy, Progressive Multifocal/drug therapy; Leukoencephalopathy, Progressive Multifocal/therapy; Prognosis; Treatment Outcome

Sujets proches En

Therapy

Citer ce document

R. Bernard-Valnet et al., « Advances in Treatment of Progressive Multifocal Leukoencephalopathy. », Serveur académique Lausannois, ID : 10.1002/ana.26198

Métriques

Partage / Export

Résumé 0

Progressive multifocal encephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by JC virus (JCV), which occurs in immunocompromised individuals. Management of PML relies on restoration of immunity within the CNS. However, when this restoration cannot be readily achieved, PML has a grim prognosis. Innovative strategies have shown promise in promoting anti-JCV immune responses, and include T-cell adoptive transfer or immune checkpoint inhibitor therapies. Conversely, management of immune reconstitution inflammatory syndrome, particularly in iatrogenic PML, remains a major challenge. In this paper, we review recent development in the treatment of PML. ANN NEUROL 2021;90:865-873.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en